Literature DB >> 22452339

Gut hormones: the future of obesity treatment?

Anne K McGavigan1, Kevin G Murphy.   

Abstract

Obesity is a major worldwide health problem. The treatment options are severely limited. The development of novel anti-obesity drugs is fraught with efficacy and safety issues. Consequently, several investigational anti-obesity drugs have failed to gain marketing approval in recent years. Anorectic gut hormones offer a potentially safe and viable option for the treatment of obesity. The prospective utility of gut hormones has improved drastically in recent years with the development of longer acting analogues. Additionally, specific combinations of gut hormones have been demonstrated to have additive anorectic effects. This article reviews the current stage of anti-obesity drugs in development, focusing on gut hormone-based therapies.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Mesh：

Substances：

Year:  2012        PMID： 22452339      PMCID： PMC3522804          DOI： 10.1111/j.1365-2125.2012.04278.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  76 in total

1.  Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.

Authors:  Nicola M Neary; Caroline J Small; Maralyn R Druce; Adrian J Park; Sandra M Ellis; Nina M Semjonous; Catherine L Dakin; Karin Filipsson; Fang Wang; Aysha S Kent; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom
Journal:  Endocrinology       Date:  2005-09-08       Impact factor: 4.736

Review 2.  Strategies to improve oral drug bioavailability.

Authors:  Isabel Gomez-Orellana
Journal:  Expert Opin Drug Deliv       Date:  2005-05       Impact factor: 6.648

3.  A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.

Authors:  Lynn B DeCarr; Thomas M Buckholz; Lucinda F Milardo; Michelle R Mays; Astrid Ortiz; Kevin J Lumb
Journal:  Bioorg Med Chem Lett       Date:  2007-01-24       Impact factor: 2.823

4.  Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.

Authors:  Prasanth K Chelikani; Alvin C Haver; Roger D Reidelberger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-02-17       Impact factor: 3.619

5.  Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects.

Authors:  Birgitte Sloth; Jens Juul Holst; Anne Flint; Nikolaj Ture Gregersen; Arne Astrup
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-12-05       Impact factor: 4.310

6.  Effect of peptide YY3-36 on food intake in humans.

Authors:  Lukas Degen; Sibylle Oesch; Michel Casanova; Stefanie Graf; Silvia Ketterer; Juergen Drewe; Christoph Beglinger
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

7.  Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.

Authors:  K Wynne; A J Park; C J Small; K Meeran; M A Ghatei; G S Frost; S R Bloom
Journal:  Int J Obes (Lond)       Date:  2006-04-18       Impact factor: 5.095

8.  Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.

Authors:  C M Mack; C X Moore; C M Jodka; S Bhavsar; J K Wilson; J A Hoyt; J L Roan; C Vu; K D Laugero; D G Parkes; A A Young
Journal:  Int J Obes (Lond)       Date:  2006-03-14       Impact factor: 5.095

9.  Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.

Authors:  Katie Wynne; Adrian J Park; Caroline J Small; Michael Patterson; Sandra M Ellis; Kevin G Murphy; Alison M Wren; Gary S Frost; Karim Meeran; Mohammad A Ghatei; Stephen R Bloom
Journal:  Diabetes       Date:  2005-08       Impact factor: 9.461

10.  Low-dose pancreatic polypeptide inhibits food intake in man.

Authors:  David R Jesudason; Mariana P Monteiro; Barbara M C McGowan; Nicola M Neary; Adrian J Park; Elena Philippou; Caroline J Small; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom
Journal:  Br J Nutr       Date:  2007-03       Impact factor: 3.718
View more
  6 in total

Review 1.  Gut fat signaling and appetite control with special emphasis on the effect of thylakoids from spinach on eating behavior.

Authors:  C J Rebello; C E O'Neil; F L Greenway
Journal:  Int J Obes (Lond)       Date:  2015-07-31       Impact factor: 5.095

2.  High molecular weight PEGylation of human pancreatic polypeptide at position 22 improves stability and reduces food intake in mice.

Authors:  V Thieme; N Jolly; A N Madsen; K Bellmann-Sickert; T W Schwartz; B Holst; H M Cox; A G Beck-Sickinger
Journal:  Br J Pharmacol       Date:  2016-10-05       Impact factor: 8.739

3.  Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.

Authors:  Hiroaki Nagai; Tomoko Kaisho; Kotaro Yokoyama; Tomoko Asakawa; Hisashi Fujita; Kouta Matsumiya; Jiro Noguchi; Kazue Tsuchimori; Naoki Nishizawa; Yoko Kanematsu-Yamaki; Katsuko Dote; Hiroshi Inooka; Jun-Ichi Sakamoto; Tetsuya Ohtaki; Taiji Asami; Shiro Takekawa
Journal:  Br J Pharmacol       Date:  2017-12-18       Impact factor: 8.739

Review 4.  Brain delivery of proteins via their fatty acid and block copolymer modifications.

Authors:  Xiang Yi; Alexander V Kabanov
Journal:  J Drug Target       Date:  2013-12       Impact factor: 5.121

Review 5.  Obesity pharmacotherapy: current perspectives and future directions.

Authors:  Monika Misra
Journal:  Curr Cardiol Rev       Date:  2013-02-01

6.  Patient awareness about the indications and complications of sleeve gastrectomy.

Authors:  Zaki H Al Watban; Omar A Al Sulaiman; Mohammad S Al Suhaibani; Ibrahim Y Al Nafisah; Ibrahim M Al Ateiq; Yousef A Al Samil; Yousef A Al Turki
Journal:  J Family Med Prim Care       Date:  2020-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.